MCID: CRR012
MIFTS: 22

Cirrhotic Cardiomyopathy

Categories: Liver diseases, Rare diseases, Cardiovascular diseases

Aliases & Classifications for Cirrhotic Cardiomyopathy

MalaCards integrated aliases for Cirrhotic Cardiomyopathy:

Name: Cirrhotic Cardiomyopathy 59

Characteristics:

Orphanet epidemiological data:

59
cirrhotic cardiomyopathy
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

Orphanet 59 ORPHA57777
ICD10 via Orphanet 34 I42.8

Summaries for Cirrhotic Cardiomyopathy

MalaCards based summary : Cirrhotic Cardiomyopathy is related to liver disease and hepatorenal syndrome. An important gene associated with Cirrhotic Cardiomyopathy is NPPA (Natriuretic Peptide A). The drugs Metoprolol and Adrenergic Agents have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and brain.

Related Diseases for Cirrhotic Cardiomyopathy

Diseases related to Cirrhotic Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 liver disease 9.9
2 hepatorenal syndrome 9.9
3 hepatopulmonary syndrome 9.9
4 budd-chiari syndrome 9.7
5 hepatitis 9.7
6 liver cirrhosis 9.7
7 portal hypertension 9.7
8 hepatic encephalopathy 9.7
9 peritonitis 9.7
10 encephalopathy 9.7

Graphical network of the top 20 diseases related to Cirrhotic Cardiomyopathy:



Diseases related to Cirrhotic Cardiomyopathy

Symptoms & Phenotypes for Cirrhotic Cardiomyopathy

Drugs & Therapeutics for Cirrhotic Cardiomyopathy

Drugs for Cirrhotic Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
2 Adrenergic Agents Phase 3,Not Applicable
3 Adrenergic Antagonists Phase 3,Not Applicable
4 Adrenergic beta-1 Receptor Antagonists Phase 3
5 Adrenergic beta-Antagonists Phase 3,Not Applicable
6 Sympatholytics Phase 3
7 Neurotransmitter Agents Phase 3,Not Applicable
8 Anti-Arrhythmia Agents Phase 3
9 Peripheral Nervous System Agents Phase 3
10 Antihypertensive Agents Phase 3,Not Applicable
11 Autonomic Agents Phase 3
12
Dobutamine Approved 34368-04-2 36811
13
Carvedilol Approved, Investigational Not Applicable 72956-09-3 2585
14 Liver Extracts ,Not Applicable
15 Adrenergic Agonists
16 Adrenergic alpha-1 Receptor Antagonists Not Applicable
17 Adrenergic alpha-Antagonists Not Applicable
18 Adrenergic beta-Agonists
19 Vasodilator Agents Not Applicable
20 Antioxidants Not Applicable
21 Protective Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis Completed NCT01676285 Phase 3 Metoprolol succinate;placebo
2 Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events Unknown status NCT01433848
3 DOCICAR: Cardiac Dysfunction in Cirrhosis Completed NCT00250315 Dobutamine
4 Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality Completed NCT02294292 Not Applicable Carvedilol;Ivabradine
5 Heart Rate Variability Change After Liver Transplantation Completed NCT00778687
6 Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis Completed NCT01713478 Not Applicable
7 Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment Recruiting NCT03443934

Search NIH Clinical Center for Cirrhotic Cardiomyopathy

Genetic Tests for Cirrhotic Cardiomyopathy

Anatomical Context for Cirrhotic Cardiomyopathy

MalaCards organs/tissues related to Cirrhotic Cardiomyopathy:

41
Liver, Heart, Brain

Publications for Cirrhotic Cardiomyopathy

Articles related to Cirrhotic Cardiomyopathy:

(show top 50) (show all 79)
# Title Authors Year
1
Extracorporeal Membrane Oxygenation in a Patient With Cirrhotic Cardiomyopathy. ( 29555386 )
2018
2
Cirrhotic cardiomyopathy. ( 29716752 )
2018
3
Cirrhotic cardiomyopathy after transplantation: Neither the transient nor innocent bystander. ( 29672903 )
2018
4
I^-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. ( 29979644 )
2018
5
Hepatic encephalopathy and cirrhotic cardiomyopathy in intensive care unit. ( 29624025 )
2018
6
Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes. ( 29637720 )
2018
7
Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver. ( 29368192 )
2018
8
The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy. ( 29453929 )
2018
9
Cirrhotic Cardiomyopathy: A New Clinical Phenotype. ( 28699978 )
2017
10
Cirrhotic cardiomyopathy: Implications for liver transplantation. ( 28407402 )
2017
11
Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease? ( 28245727 )
2017
12
Fragmented QRS is associated with cirrhotic cardiomyopathy in patients with decompensated cirrhosis. ( 27382936 )
2016
13
Galactin-3 and brain natriuretic peptide versus conventional echocardiography in the early detection of cirrhotic cardiomyopathy. ( 27458853 )
2016
14
Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy. ( 27217700 )
2016
15
Minocycline attenuates cirrhotic cardiomyopathy and portal hypertension in a rat model: Possible involvement of nitric oxide pathway. ( 27917279 )
2016
16
Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. ( 27843430 )
2016
17
Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis? ( 26839643 )
2016
18
The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease. ( 28053679 )
2016
19
Prevalence of cirrhotic cardiomyopathy in patients with cirrhosis of liver. ( 27727569 )
2016
20
Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. ( 27292629 )
2016
21
Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. ( 26187817 )
2015
22
Cirrhotic cardiomyopathy. ( 26556983 )
2015
23
Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. ( 25874140 )
2015
24
Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. ( 26074443 )
2015
25
Anti-Apoptosis Effects on Hearts of SHSST Cyclodextrin Complex in a Carbon Tetrachloride-induced Cirrhotic Cardiomyopathy Rat Model. ( 25687490 )
2015
26
Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. ( 25974637 )
2015
27
Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. ( 25848474 )
2015
28
Diastolic dysfunction characterizes cirrhotic cardiomyopathy. ( 25634400 )
2014
29
Cirrhotic cardiomyopathy: review of pathophysiology and treatment. ( 25221635 )
2014
30
Opioid receptors blockade modulates apoptosis in a rat model of cirrhotic cardiomyopathy. ( 24971217 )
2014
31
Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice. ( 24712830 )
2014
32
Cirrhotic cardiomyopathy. ( 25870696 )
2014
33
Pathophysiological and clinical approach to cirrhotic cardiomyopathy. ( 25267959 )
2014
34
SHSST cyclodextrin complex prevents the fibrosis effect on CCla88-induced cirrhotic cardiomyopathy in rats through TGF-I^ pathway inhibition effects. ( 24815066 )
2014
35
Recent Advances in Cirrhotic Cardiomyopathy. ( 25404411 )
2014
36
Cirrhotic cardiomyopathy: A cardiologist's perspective. ( 25400434 )
2014
37
Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. ( 23907333 )
2013
38
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. ( 23995321 )
2013
39
New insights into cirrhotic cardiomyopathy. ( 23041091 )
2013
40
Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. ( 24217347 )
2013
41
Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. ( 23615223 )
2013
42
Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. ( 22835858 )
2012
43
The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. ( 23245476 )
2012
44
A perspective on cirrhotic cardiomyopathy. ( 21693251 )
2011
45
High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. ( 21276088 )
2011
46
The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy. ( 20414815 )
2010
47
Cirrhotic cardiomyopathy. ( 20688208 )
2010
48
Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. ( 21415581 )
2010
49
Perioperative considerations in patients with cirrhotic cardiomyopathy. ( 20124994 )
2010
50
Cirrhotic cardiomyopathy. ( 20462649 )
2010

Variations for Cirrhotic Cardiomyopathy

Expression for Cirrhotic Cardiomyopathy

Search GEO for disease gene expression data for Cirrhotic Cardiomyopathy.

Pathways for Cirrhotic Cardiomyopathy

GO Terms for Cirrhotic Cardiomyopathy

Sources for Cirrhotic Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....